Evidence map›Paper›PMID 35954266›Full record

ArticleCells2022

Differentiation of Human Induced Pluripotent Stem Cells from Patients with Severe COPD into Functional Airway Epithelium.

Engi Ahmed, Mathieu Fieldes, Chloé Bourguignon, Joffrey Mianné, Aurélie Petit, Myriam Jory, Chantal Cazevieille, Hassan Boukhaddaoui, James P Garnett, Christophe Hirtz and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Engi AhmedIRMB, University Montpellier, INSERM, CHU Montpellier, F-34000 Montpellier, France.
Mathieu FieldesIRMB, University Montpellier, INSERM, CHU Montpellier, F-34000 Montpellier, France.
Chloé BourguignonIRMB, University Montpellier, INSERM, CHU Montpellier, F-34000 Montpellier, France.
Joffrey MiannéIRMB, University Montpellier, INSERM, CHU Montpellier, F-34000 Montpellier, France.ORCID 0000-0003-0893-9947
Aurélie PetitDepartment of Respiratory Diseases, University Montpellier, CHU Montpellier, Hôpital Arnaud de Villeneuve, F-34000 Montpellier, France.ORCID 0000-0002-9069-9868
Myriam JoryCentre National de la Recherche Scientifique UMR 5221, Laboratoire Charles Coulomb, University Montpellier, F-34000 Montpellier, France.
Chantal CazevieilleInstitut des Neurosciences de Montpellier, University Montpellier, F-34000 Montpellier, France.
Hassan BoukhaddaouiInstitut des Neurosciences de Montpellier, University Montpellier, F-34000 Montpellier, France.
James P GarnettImmunology & Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 Biberach an der Riss, Germany.
Christophe HirtzIRMB, University Montpellier, INSERM, CHU Montpellier, F-34000 Montpellier, France.
Gladys MassieraCentre National de la Recherche Scientifique UMR 5221, Laboratoire Charles Coulomb, University Montpellier, F-34000 Montpellier, France.
Isabelle VachierDepartment of Respiratory Diseases, University Montpellier, CHU Montpellier, Hôpital Arnaud de Villeneuve, F-34000 Montpellier, France.ORCID 0000-0003-2730-5165
Said AssouIRMB, University Montpellier, INSERM, CHU Montpellier, F-34000 Montpellier, France.ORCID 0000-0001-6448-7995
Arnaud BourdinDepartment of Respiratory Diseases, University Montpellier, CHU Montpellier, Hôpital Arnaud de Villeneuve, F-34000 Montpellier, France.
John De VosIRMB, University Montpellier, INSERM, CHU Montpellier, F-34000 Montpellier, France.ORCID 0000-0003-1880-4130
Inserm · FRCentre National de la Recherche Scientifique · FRHôpital Arnaud de Villeneuve · FRInstitute for Neurosciences of Montpellier · FRBoehringer Ingelheim (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD), a major cause of mortality and disability, is a complex disease with heterogeneous and ill-understood biological mechanisms. Human induced pluripotent stem cells (hiPSCs) are a promising tool to model human disease, including the impact of genetic susceptibility. Methods: We developed a simple and reliable method for reprogramming peripheral blood mononuclear cells into hiPSCs and to differentiate them into air−liquid interface bronchial epithelium within 45 days. Importantly, this method does not involve any cell sorting step. We reprogrammed blood cells from one healthy control and three patients with very severe COPD. Results: The mean cell purity at the definitive endoderm and ventral anterior foregut endoderm (vAFE) stages was >80%, assessed by quantifying C-X-C Motif Chemokine Receptor 4/SRY-Box Transcription Factor 17 (CXCR4/SOX17) and NK2 Homeobox 1 (NKX2.1) expression, respectively. vAFE cells from all four hiPSC lines differentiated into bronchial epithelium in air−liquid interface conditions, with large zones covered by beating ciliated, basal, goblets, club cells and neuroendocrine cells, as found in vivo. The hiPSC-derived airway epithelium (iALI) from patients with very severe COPD and from the healthy control were undistinguishable. Conclusions: iALI bronchial epithelium is ready for better understanding lung disease pathogenesis and accelerating drug discovery.

Indexed as

Induced Pluripotent Stem CellsPulmonary Disease, Chronic ObstructiveEpitheliumHumansLeukocytes, MononuclearRespiratory Mucosaairway epitheliumchronic obstructive pulmonary diseasedisease modelinghuman induced pluripotent stem cells

Identifiers

PMID35954266
PMCPMC9368529
OpenAlexW4290466614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.